Literature DB >> 2364263

Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys.

J R Taylor1, J D Elsworth, R H Roth, J R Sladek, D E Redmond.   

Abstract

To assess functional changes following treatment with 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) in monkeys, we studied a task that reveals sensitivity to dopamine deficits under various conditions. The task required retrieval of a banana slice from a transparent box that is open on one side and fastened to a tray. Successful performance required the subject to suppress a tendency to reach directly at the reward while (1) orientation of the open side, (2) position on the tray, and (3) position of the banana in the box were manipulated in order to vary the cognitive and motor difficulty of the trial. African green monkeys (Cercopithecus aethiops sabaeus) were treated with MPTP (1.5-1.6 mg/kg cumulative dose over 4-5 days). A control group was sham treated (n = 12). MPTP-treated subjects either became severely symptomatic, showing motor impairments that prevented them from performing, or showed no gross motor impairment (n = 6) in spite of major depletions in dopamine concentrations. MPTP-treated subjects showed impaired acquisition of the task when tested 8-12 months later. They made more errors during the sessions, specifically on the trials that were related to cognitive complexity, such as attempting to reach directly towards the reward through the transparent side of the box (a barrier reach), instead of reaching around it (detour) into the open side, as well as other awkward, perseverative or delayed reaches. MPTP appears to cause both cognitive and motor deficits in the acquisition of this task 8-12 months after treatment, even in the group of monkeys which never showed gross motor deficits.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2364263     DOI: 10.1093/brain/113.3.617

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  27 in total

1.  Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys.

Authors:  D M Lyons; J M Lopez; C Yang; A F Schatzberg
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

3.  Residual lesions of operant behavior in monkeys following recovery from MPTP-induced Parkinson-like syndrome.

Authors:  A V Latanov; L V Tereshchenko; A G Yudin; V V Shul'govskii
Journal:  Neurosci Behav Physiol       Date:  1998 Jul-Aug

4.  Cognition-impairing effects of benzodiazepine-type drugs: role of GABAA receptor subtypes in an executive function task in rhesus monkeys.

Authors:  Leah Makaron; Casey A Moran; Ojas Namjoshi; Sundari Rallapalli; James M Cook; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

Review 5.  Prefrontal dysfunction and a monkey model of schizophrenia.

Authors:  Ping Mao; Ding Cui; Xu-Dong Zhao; Yuan-Ye Ma
Journal:  Neurosci Bull       Date:  2015-03-31       Impact factor: 5.203

6.  Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease.

Authors:  S Palfi; R J Ferrante; E Brouillet; M F Beal; R Dolan; M C Guyot; M Peschanski; P Hantraye
Journal:  J Neurosci       Date:  1996-05-01       Impact factor: 6.167

Review 7.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

8.  Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.

Authors:  Joshua D Vardigan; Christopher E Cannon; Vanita Puri; Mandy Dancho; AmyJo Koser; Marion Wittmann; Scott D Kuduk; John J Renger; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

Review 9.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

10.  Reaching around barriers: the performance of the great apes and 3-5-year-old children.

Authors:  Petra H J M Vlamings; Brian Hare; Josep Call
Journal:  Anim Cogn       Date:  2009-08-04       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.